Evoke PharmaEVOK
13F holders, Q1 2025 (March 31)10holders +2
3new positions
1sold out
1famous investor
$2.59avg. 13F price*
At the end of Q1 2025, 10 institutions reported holding Evoke Pharma Inc. (EVOK) in their 13F filings, up 2 from Q4 2024. 3 opened new positions and 1 sold out. The largest holders were Nantahala Capital Management, LLC ($407K), Bleichroeder LP ($189K) and Citadel Advisors ($68K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Evoke Pharma Inc.
- CUSIP
- 30049G302
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $81K |
| Exits | 1 | $6K |
All 13F filers, Q4 2024 → Q1 2025: 45,049 shares bought and 1,299 shares sold, net +43,750 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Nantahala Capital Management, LLC | 0.03% | Reduce -0.0% | 148,153 | $407K |
| Bleichroeder LP | 0.05% | No change | 68,750 | $189K |
| Citadel Advisors | 0.00% | New | 24,803 | $68K |
| BRC Group Holdings, Inc. | 0.02% | New | 20,000 | $12K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 213 | $586 |
| BlackRock, Inc. | 0.00% | No change | 122 | $336 |
| SBI Securities Co., Ltd. | 0.00% | No change | 75 | $206 |
| Morgan Stanley | 0.00% | Add +106.5% | 64 | $176 |
| NewEdge Advisors, LLC | 0.00% | No change | 17 | $47 |
| Bank of America Corp. | 0.00% | No change | 9 | $25 |
"% of holder's portfolio" is EVOK's weight in each manager's 13F, not the share of Evoke Pharma Inc. the manager owns.